Non‐small cell lung cancer in China

P Chen, Y Liu, Y Wen, C Zhou - Cancer Communications, 2022 - Wiley Online Library
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D Planchard, ST Popat, K Kerr, S Novello… - Annals of …, 2018 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung …

C Zhou, G Chen, Y Huang, J Zhou, LZ Lin… - The Lancet …, 2021 - thelancet.com
Background Immunotherapy combined with chemotherapy has been shown to be
efficacious as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) …

Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC

MA Socinski, RM Jotte, F Cappuzzo… - … England Journal of …, 2018 - Mass Medical Soc
Background The cancer-cell–killing property of atezolizumab may be enhanced by the
blockade of vascular endothelial growth factor–mediated immunosuppression with …

[HTML][HTML] New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment

SH Chen, JY Chang - International journal of molecular sciences, 2019 - mdpi.com
Although cisplatin has been a pivotal chemotherapy drug in treating patients with various
types of cancer for decades, drug resistance has been a major clinical impediment. In …

Tumor angiogenesis and vascular normalization: alternative therapeutic targets

C Viallard, B Larrivée - Angiogenesis, 2017 - Springer
Tumor blood vessels are a key target for cancer therapeutic management. Tumor cells
secrete high levels of pro-angiogenic factors which contribute to the creation of an abnormal …

Vessel co-option in cancer

EA Kuczynski, PB Vermeulen, F Pezzella… - Nature reviews Clinical …, 2019 - nature.com
All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

MD Hellmann, NA Rizvi, JW Goldman… - The lancet …, 2017 - thelancet.com
Background Nivolumab has shown improved survival in the treatment of advanced non-
small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the …

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

S Novello, F Barlesi, R Califano, T Cufer… - Annals of …, 2016 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …